

# Robin L Jones

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9179431/publications.pdf>

Version: 2024-02-01

399  
papers

17,141  
citations

18482  
62  
h-index

20358  
116  
g-index

413  
all docs

413  
docs citations

413  
times ranked

17134  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. <i>Clinical Cancer Research</i> , 2022, 28, 1672-1679.	7.0	18
2	Risk factors for the development of local recurrence in extremity soft-tissue sarcoma. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 83-95.	2.4	6
3	Development of a Disease-Specific Health-Related Quality of Life Questionnaire (DTF-QoL) for Patients with Desmoid-Type Fibromatosis. <i>Cancers</i> , 2022, 14, 709.	3.7	8
4	KIT Exon 9-Mutated Gastrointestinal Stromal Tumours: Biology and Treatment. <i>Chemotherapy</i> , 2022, 67, 81-90.	1.6	10
5	Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells. <i>Clinical Cancer Research</i> , 2022, 28, 1701-1711.	7.0	17
6	Current Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas. <i>Biomedicines</i> , 2022, 10, 573.	3.2	8
7	Immunologic Gene Signature Analysis Correlates Myeloid Cells and M2 Macrophages with Time to Trabectedin Failure in Sarcoma Patients. <i>Cancers</i> , 2022, 14, 1290.	3.7	5
8	Efficacy of Eribulin in Soft Tissue Sarcomas. <i>Frontiers in Pharmacology</i> , 2022, 13, 869754.	3.5	9
9	Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma. <i>JAMA Oncology</i> , 2022, 8, 740.	7.1	12
10	A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 2306-2312.	7.0	17
11	Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature. <i>Cancers</i> , 2022, 14, 1832.	3.7	15
12	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2479-2490.	1.6	15
13	Machine learning for rhabdomyosarcoma histopathology. <i>Modern Pathology</i> , 2022, 35, 1193-1203.	5.5	9
14	Proteomic Profiling Identifies Co-Regulated Expression of Splicing Factors as a Characteristic Feature of Intravenous Leiomyomatosis. <i>Cancers</i> , 2022, 14, 2907.	3.7	2
15	Unraveling Desmoid-Type Fibromatosis-Specific Health-Related Quality of Life: Who Is at Risk for Poor Outcomes. <i>Cancers</i> , 2022, 14, 2979.	3.7	5
16	Management of Vascular Sarcoma. <i>Surgical Oncology Clinics of North America</i> , 2022, 31, 485-510.	1.5	2
17	Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study. <i>European Journal of Cancer</i> , 2022, 171, 183-192.	2.8	4
18	Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. <i>Annals of Surgical Oncology</i> , 2022, 29, 7335-7348.	1.5	13

#	ARTICLE	IF	CITATIONS
19	Immunotherapy of sarcomas with modified T cells. <i>Current Opinion in Oncology</i> , 2022, 34, 362-370.	2.4	5
20	Functional genomic analysis of epithelioid sarcoma reveals distinct proximal and distal subtype biology. <i>Clinical and Translational Medicine</i> , 2022, 12, .	4.0	6
21	SMARCA4-Deficient Thoracic Sarcoma. <i>International Journal of Surgical Pathology</i> , 2021, 29, 640-641.	0.8	3
22	<i>EWSR1-SMAD3</i> -Positive Fibroblastic Tumor. <i>International Journal of Surgical Pathology</i> , 2021, 29, 179-181.	0.8	7
23	Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 132-141.	4.1	9
24	Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors. <i>Oncologist</i> , 2021, 26, e622-e631.	3.7	20
25	Sirolimus for patients with progressive epithelioid hemangioendothelioma. <i>Cancer</i> , 2021, 127, 504-506.	4.1	3
26	Gynecological Sarcomas: Molecular Characteristics, Behavior, and Histology-Driven Therapy. <i>International Journal of Surgical Pathology</i> , 2021, 29, 4-20.	0.8	6
27	Current Reality of Treating Advanced Soft Tissue Sarcoma as Illustrated by Case Studies. <i>Oncology</i> , 2021, 99, 8-16.	1.9	0
28	The role of [ <sup>68</sup> Ga]Ga-DOTATATE PET/CT in wild-type KIT/PDGFRα gastrointestinal stromal tumours (GIST). <i>EJNMMI Research</i> , 2021, 11, 5.	2.5	4
29	Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients—A Position Paper from the National Leiomyosarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN). <i>Cancers</i> , 2021, 13, 886.	3.7	17
30	Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy. <i>Oncologist</i> , 2021, 26, e639-e649.	3.7	29
31	Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial. <i>Clinical Cancer Research</i> , 2021, 27, 3861-3866.	7.0	22
32	Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas. <i>Npj Precision Oncology</i> , 2021, 5, 17.	5.4	23
33	Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. <i>Cancer Medicine</i> , 2021, 10, 2645-2659.	2.8	23
34	Avapritinib in unresectable or metastatic PDGFRα D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. <i>European Journal of Cancer</i> , 2021, 145, 132-142.	2.8	75
35	Extraskeletal osteosarcomas: current update. <i>Future Oncology</i> , 2021, 17, 825-835.	2.4	8
36	Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. <i>Cancer</i> , 2021, 127, 2934-2942.	4.1	96

#	ARTICLE	IF	CITATIONS
37	Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group. <i>Annals of Surgical Oncology</i> , 2021, 28, 7873-7888.	1.5	105
38	Intra-patient dose escalation (IPDE) of ripretinib after disease progression in patients with advanced gastrointestinal stromal tumor (GIST): Analyses from the phase 3 INVICTUS study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11536-11536.	1.6	0
39	IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy. , 2021, 9, e002232.		10
40	Phase (Ph) 1b/2 evaluation of olaratumab in combination with gemcitabine and docetaxel in advanced soft tissue sarcoma (STS).. <i>Journal of Clinical Oncology</i> , 2021, 39, 11517-11517.	1.6	2
41	Next-generation sequencing for the management of sarcomas with no known driver mutations. <i>Current Opinion in Oncology</i> , 2021, 33, 315-322.	2.4	13
42	Managing the risk of toxicity in the treatment of elderly patients with soft tissue sarcomas. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 903-913.	2.4	1
43	Clinical management and outcomes of primary ovarian leiomyosarcoma “ Experience from a sarcoma specialist unit. <i>Gynecologic Oncology Reports</i> , 2021, 36, 100737.	0.6	9
44	Results of the phase 1b soft-tissue sarcoma (STS) portion of the global randomized, double-blind, placebo-controlled study of tazemetostat (TAZ) plus doxorubicin (DOX) as frontline therapy for advanced epithelioid sarcoma (ES).. <i>Journal of Clinical Oncology</i> , 2021, 39, 11563-11563.	1.6	2
45	Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer. <i>Cancer Medicine</i> , 2021, 10, 3565-3574.	2.8	6
46	Proteomic profiling of soft tissue sarcomas with SWATH mass spectrometry. <i>Journal of Proteomics</i> , 2021, 241, 104236.	2.4	12
47	Articulatory Correlates of Stress Pattern Disturbances in Talkers With Dysarthria. <i>Journal of Speech, Language, and Hearing Research</i> , 2021, 64, 2287-2300.	1.6	4
48	The Evaluation of Health-Related Quality of Life Issues Experienced by Patients with Desmoid-Type Fibromatosis (The QUALIFIED Study)“A Protocol for an International Cohort Study. <i>Cancers</i> , 2021, 13, 3068.	3.7	9
49	Fibroblast Growth Factor Receptor (FGFR) Signaling in GIST and Soft Tissue Sarcomas. <i>Cells</i> , 2021, 10, 1533.	4.1	14
50	What Matters to Us: Impact of Telemedicine During the Pandemic in the Care of Patients With Sarcoma Across Scotland. <i>JCO Global Oncology</i> , 2021, 7, 1067-1073.	1.8	9
51	The evolving management of epithelioid sarcoma. <i>European Journal of Cancer Care</i> , 2021, 30, e13489.	1.5	5
52	Abstract CT123: Population pharmacokinetics of ripretinib in patients with advanced malignancies. <i>Cancer Research</i> , 2021, 81, CT123-CT123.	0.9	1
53	Pharmacotherapy for liposarcoma: current and emerging synthetic treatments. <i>Future Oncology</i> , 2021, 17, 2659-2670.	2.4	6
54	CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes. , 2021, 9, e002812.		21

#	ARTICLE	IF	CITATIONS
55	Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2173-2181.	1.0	2
56	Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the <scp>INVICTUS</scp> Study. <i>Oncologist</i> , 2021, 26, e2053-e2060.	3.7	19
57	Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. <i>Future Oncology</i> , 2021, 17, 2923-2939.	2.4	10
58	Ripretinib inpatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. <i>European Journal of Cancer</i> , 2021, 155, 236-244.	2.8	19
59	Desmoid fibromatosis: is the current picture changing?. <i>Future Oncology</i> , 2021, 17, 3397-3408.	2.4	5
60	Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous <i>KIT/PDGFRA</i> Mutations in the Phase III INVICTUS Study. <i>Clinical Cancer Research</i> , 2021, 27, 6333-6342.	7.0	25
61	Solitary fibrous tumor: molecular hallmarks and treatment for a rare sarcoma. <i>Future Oncology</i> , 2021, 17, 3627-3636.	2.4	15
62	Gastrointestinal leiomyosarcoma demonstrate a predilection for distant recurrence and poor response to systemic treatments. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2595-2601.	1.0	3
63	Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3128-3139.	1.6	56
64	Future Directions in the Treatment of Osteosarcoma. <i>Cells</i> , 2021, 10, 172.	4.1	102
65	Olaratumab-induced Biomarker Modulation in Sarcomasâ€”Response. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2094-2094.	4.1	0
66	The perplexing role of immuno-oncology drugs in osteosarcoma. <i>Journal of Bone Oncology</i> , 2021, 31, 100400.	2.4	4
67	Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. <i>Nature Cancer</i> , 2021, 2, 1321-1337.	13.2	66
68	Dedifferentiated chondrosarcoma: current standards of care. <i>Future Oncology</i> , 2021, 17, 4983-4991.	2.4	2
69	The Extracellular Matrix in Soft Tissue Sarcomas: Pathobiology and Cellular Signalling. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 763640.	3.7	7
70	Imaging features of primary sites and metastatic patterns of angiosarcoma. <i>Insights Into Imaging</i> , 2021, 12, 189.	3.4	3
71	Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy. <i>European Urology Focus</i> , 2020, 6, 999-1005.	3.1	5
72	Subgroup analysis of older patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARC021) trial. <i>Journal of Geriatric Oncology</i> , 2020, 11, 463-469.	1.0	7

#	ARTICLE	IF	CITATIONS
73	Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. <i>Cancer</i> , 2020, 126, 98-104.	4.1	25
74	Embryonal and Alveolar Rhabdomyosarcoma in Adults: Real-Life Data From a Tertiary Sarcoma Centre. <i>Clinical Oncology</i> , 2020, 32, e27-e35.	1.4	12
75	Proteomic research in sarcomas – current status and future opportunities. <i>Seminars in Cancer Biology</i> , 2020, 61, 56-70.	9.6	50
76	Toxicity management of regorafenib in patients with gastro-intestinal stromal tumour (GIST) in a tertiary cancer centre. <i>Clinical Sarcoma Research</i> , 2020, 10, 1.	2.3	23
77	Adult soft tissue myoepithelial carcinoma: treatment outcomes and efficacy of chemotherapy. <i>Medical Oncology</i> , 2020, 37, 13.	2.5	18
78	Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. <i>ESMO Open</i> , 2020, 5, e000787.	4.5	22
79	Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. <i>Annals of Oncology</i> , 2020, 31, 1506-1517.	1.2	103
80	Diagnostic Differences in Expert Second-Opinion Consultation Cases at a Tertiary Sarcoma Center. <i>Sarcoma</i> , 2020, 2020, 1-11.	1.3	15
81	A Timely Oral Option: Single-Agent Vinorelbine in Desmoid Tumors. <i>Oncologist</i> , 2020, 25, e2013-e2016.	3.7	13
82	Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. <i>Lancet Oncology</i> , The, 2020, 21, 1423-1432.	10.7	194
83	Telemedicine During the COVID-19 Pandemic: Impact on Care for Rare Cancers. <i>JCO Global Oncology</i> , 2020, 6, 1046-1051.	1.8	89
84	Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer. <i>European Journal of Cancer</i> , 2020, 136, 99-106.	2.8	31
85	Optimal Clinical Management and the Molecular Biology of Angiosarcomas. <i>Cancers</i> , 2020, 12, 3321.	3.7	15
86	Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma. <i>JAMA Oncology</i> , 2020, 6, 1778.	7.1	66
87	Epithelioid malignant peripheral nerve sheath tumor arising in schwannoma. <i>Rare Tumors</i> , 2020, 12, 203636132095086.	0.6	6
88	Paraneoplastic dermatomyositis associated with metastatic leiomyosarcoma of unknown primary. <i>Clinical Sarcoma Research</i> , 2020, 10, 15.	2.3	2
89	Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. <i>Journal of Clinical Oncology</i> , 2020, 38, 3294-3303.	1.6	61
90	Health-Related Quality of Life and Experiences of Sarcoma Patients during the COVID-19 Pandemic. <i>Cancers</i> , 2020, 12, 2288.	3.7	49

#	ARTICLE	IF	CITATIONS
91	Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue. <i>Anticancer Research</i> , 2020, 40, 7003-7007.	1.1	3
92	1621MO Long-term efficacy, tolerability and overall survival in patients (pts) with unresectable or metastatic (U/M) PDGFRA D842V-mutant gastrointestinal stromal tumour (GIST) treated with avapritinib: NAVIGATOR phase I trial update. <i>Annals of Oncology</i> , 2020, 31, S973.	1.2	2
93	1622MO Clinical benefit with ripretinib as 4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study. <i>Annals of Oncology</i> , 2020, 31, S973-S974.	1.2	1
94	1623MO Ripretinib intra-patient dose escalation (IPDE) following disease progression provides clinically meaningful progression-free survival (PFS) in gastrointestinal stromal tumor (GIST) in phase I study. <i>Annals of Oncology</i> , 2020, 31, S974-S975.	1.2	3
95	1626MO Treatment expectations and preferences for quality versus quantity of life in patients with advanced soft tissue sarcomas starting palliative 1st line chemotherapy. <i>Annals of Oncology</i> , 2020, 31, S976.	1.2	0
96	1639P Integrated safety analysis of tazemetostat (TAZ) 800 mg BID in adult patients (pts) with hematologic and solid tumors. <i>Annals of Oncology</i> , 2020, 31, S981-S982.	1.2	0
97	A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1. <i>Oncolimmunology</i> , 2020, 9, 1847846.	4.6	22
98	Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland. <i>Clinical Sarcoma Research</i> , 2020, 10, 9.	2.3	5
99	Metastatic Soft Tissue Sarcomas in Adolescents and Young Adults: A Specialist Center Experience. <i>Journal of Adolescent and Young Adult Oncology</i> , 2020, 9, 628-638.	1.3	10
100	Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung. <i>Sarcoma</i> , 2020, 2020, 1-6.	1.3	17
101	Revolutions in treatment options in gastrointestinal stromal tumours (GISTs): the latest updates. <i>Current Treatment Options in Oncology</i> , 2020, 21, 55.	3.0	35
102	Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 923-934.	10.7	224
103	Robotic surgery for gastric gastrointestinal stromal tumors: A single center case series. <i>Journal of Surgical Oncology</i> , 2020, 122, 691-698.	1.7	7
104	Tropomyosin receptor kinase inhibitors in the management of sarcomas. <i>Current Opinion in Oncology</i> , 2020, 32, 307-313.	2.4	9
105	Health-related quality Of Life in patients with advanced Soft Tissue sarcomas treated with Chemotherapy (The HOLISTIC study): protocol for an international observational cohort study. <i>BMJ Open</i> , 2020, 10, e035171.	1.9	8
106	Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. <i>ESMO Open</i> , 2020, 5, e000604.	4.5	11
107	Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study. <i>British Journal of Cancer</i> , 2020, 122, 1158-1165.	6.4	17
108	Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. <i>Lancet Oncology</i> , The, 2020, 21, 935-946.	10.7	186



#	ARTICLE	IF	CITATIONS
109	O-13 Efficacy and safety of ripretinib as a 4th-line therapy for patients with gastrointestinal stromal tumor following crossover from placebo: Analyses from INVICTUS. <i>Annals of Oncology</i> , 2020, 31, 236.	1.2	3
110	Superficial CD34-Positive Fibroblastic Tumor. <i>International Journal of Surgical Pathology</i> , 2020, 28, 879-881.	0.8	7
111	Rib destruction by epithelioid tumour in a young man. <i>Journal of Clinical Pathology</i> , 2020, 73, e2-e2.	2.0	1
112	Low-grade Fibromyxoid Sarcoma: Treatment Outcomes and Efficacy of Chemotherapy. <i>In Vivo</i> , 2020, 34, 239-245.	1.3	28
113	Is the IDH Mutation a Good Target for Chondrosarcoma Treatment?. <i>Current Molecular Biology Reports</i> , 2020, 6, 1-9.	1.6	20
114	Durable tumor regression in highly refractory metastatic <i>KIT/PDGFR</i> wild-type GIST following treatment with nivolumab. <i>Oncoimmunology</i> , 2020, 9, 1710064.	4.6	8
115	Different approaches to advanced soft tissue sarcomas depending on treatment line, goal of therapy and histological subtype. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 15-28.	2.4	6
116	Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1266.	7.4	190
117	Histiocyte predominant myocarditis resulting from the addition of interferon gamma to cyclophosphamide-based lymphodepletion for adoptive cellular therapy. , 2020, 8, e000247.		7
118	The sacral chordoma margin. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1415-1422.	1.0	29
119	Perineal mass in a 50-year-old man. <i>Journal of Clinical Pathology</i> , 2020, 73, e5-e5.	2.0	1
120	The Emerging Role of Platelets in the Formation of the Micrometastatic Niche: Current Evidence and Future Perspectives. <i>Frontiers in Oncology</i> , 2020, 10, 374.	2.8	23
121	The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. <i>European Journal of Cancer</i> , 2020, 127, 96-107.	2.8	243
122	Primary ilioacaval leiomyosarcomas: The path beyond surgery. <i>European Journal of Surgical Oncology</i> , 2020, 46, 893-897.	1.0	8
123	A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113). <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1633-1637.	2.5	4
124	Quality of life (QoL) and self-reported function with ripretinib in a 4th-line therapy for patients with gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11535-11535.	1.6	8
125	Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in a fourth-line advanced gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11539-11539.	1.6	3
126	Efficacy, safety, and immune priming effect of tazemetostat in patients with epithelioid sarcoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11564-11564.	1.6	1



#	ARTICLE	IF	CITATIONS
127	The route to diagnosis of sarcoma patients: Results from an interview study in the Netherlands and the United Kingdom. PLoS ONE, 2020, 15, e0243439.	2.5	8
128	Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors. Future Oncology, 2020, 16, 1641-1648.	2.4	7
129	The adequacy of tissue microarrays in the assessment of inter- and intra-tumoural heterogeneity of infiltrating lymphocyte burden in leiomyosarcoma. Scientific Reports, 2019, 9, 14602.	3.3	22
130	Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin. Cancer, 2019, 125, 4435-4441.	4.1	10
131	The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib. Expert Review of Anticancer Therapy, 2019, 19, 971-991.	2.4	31
132	Outcome of Primary Desmoid Tumors at All Anatomic Locations Initially Managed with Active Surveillance. Annals of Surgical Oncology, 2019, 26, 4699-4706.	1.5	36
133	Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. European Journal of Cancer, 2019, 120, 132-139.	2.8	24
134	The Role of Local Therapy in Multi-focal Epithelioid Haemangioendothelioma. Anticancer Research, 2019, 39, 4891-4896.	1.1	13
135	Sarcomas and old age: few options for such a large patient population. Future Oncology, 2019, 15, 11-15.	2.4	8
136	Treatment of Desmoid Tumors in 2019. JAMA Oncology, 2019, 5, 567.	7.1	32
137	Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma. BMC Cancer, 2019, 19, 593.	2.6	13
138	Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas). Clinical Cancer Research, 2019, 25, 5295-5300.	7.0	70
139	First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. Clinical Cancer Research, 2019, 25, 5808-5817.	7.0	66
140	Systemic Interferon- $\gamma$ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial. Cancer Immunology Research, 2019, 7, 1237-1243.	3.4	82
141	Pazopanib in advanced soft tissue sarcomas. Signal Transduction and Targeted Therapy, 2019, 4, 16.	17.1	57
142	Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma. Expert Opinion on Investigational Drugs, 2019, 28, 505-511.	4.1	13
143	A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas. Cancer, 2019, 125, 2445-2454.	4.1	19
144	Aldoxorubicin in soft tissue sarcomas. Future Oncology, 2019, 15, 1429-1435.	2.4	12

#	ARTICLE	IF	CITATIONS
145	Gemcitabine Re-challenge in Metastatic Soft Tissue Sarcomas: A Therapeutic Option for Selected Patients. <i>Anticancer Research</i> , 2019, 39, 347-351.	1.1	0
146	Negative phase III trials announce the need for biomarkers in sarcoma. <i>European Journal of Cancer</i> , 2019, 123, 81-82.	2.8	1
147	Imaging Soft-tissue Sarcomas of the Head and Neck: A Tertiary Soft-tissue Sarcoma Unit Experience. <i>Anticancer Research</i> , 2019, 39, 6223-6230.	1.1	3
148	Oncological Outcome After Diagnostic Biopsies in Gastrointestinal Stromal Tumors. <i>Annals of Surgery</i> , 2019, Publish Ahead of Print, e1093-e1098.	4.2	7
149	Exposureâ€‘response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 191-199.	2.3	10
150	Optimising Cancer Vaccine Design in Sarcoma. <i>Cancers</i> , 2019, 11, 1.	3.7	211
151	Desmoid fibromatosis through the patientsâ€™ eyes: time to change the focus and organisation of care?. <i>Supportive Care in Cancer</i> , 2019, 27, 965-980.	2.2	28
152	Ending 40 years of silence: Rationale for a new staging system for soft tissue sarcoma of the head and neck. <i>Clinical and Translational Radiation Oncology</i> , 2019, 15, 13-19.	1.7	7
153	Abstract C077: Updated results of phase 1 study of ripretinib (DCC-2618), a broad-spectrum KIT and PDGFRA inhibitor, in patients with gastrointestinal stromal tumor (GIST) by line of therapy (NCT02571036). , 2019, , .		3
154	Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950).. <i>Journal of Clinical Oncology</i> , 2019, 37, 11003-11003.	1.6	50
155	ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).. <i>Journal of Clinical Oncology</i> , 2019, 37, LBA3-LBA3.	1.6	47
156	The SAINT: Initial results of a phase I/II study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 22-22.	1.6	2
157	Abstract CT058: Ripretinib (DCC-2618) pharmacokinetics (PK) in a Phase I study in patients with gastrointestinal stromal tumors (GIST) and other advanced malignancies: A retrospective evaluation of the PK effects of proton pump inhibitors (PPIs). , 2019, , .		0
158	Abstract CT009: A Phase Ib study assessing biomarker modulation in soft tissue sarcoma patients treated with olaratumab followed by olaratumab plus doxorubicin. , 2019, , .		0
159	Olaratumab in soft tissue sarcoma â€‘ Current status and future perspectives. <i>European Journal of Cancer</i> , 2018, 92, 33-39.	2.8	16
160	Endometrial Stromal Sarcoma With Hyalinizing Giant Rosettes, Mimicking Low-Grade Fibromyxoid Sarcoma. <i>International Journal of Surgical Pathology</i> , 2018, 26, 525-527.	0.8	2
161	Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma. <i>JAMA Oncology</i> , 2018, 4, e180219.	7.1	63
162	Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials. <i>Oncologist</i> , 2018, 23, 1250-1259.	3.7	25

#	ARTICLE	IF	CITATIONS
163	The current landscape of early drug development for patients with sarcoma in the immunotherapy era. <i>Future Oncology</i> , 2018, 14, 1197-1211.	2.4	11
164	Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients. <i>Acta Oncol</i> , 2018, 57, 958-964.	1.8	41
165	Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 147-151.	1.3	21
166	Safety and Efficacy Outcomes of Embolization in Hepatic Sarcomas. <i>American Journal of Roentgenology</i> , 2018, 210, 175-182.	2.2	21
167	Systemic therapy in retroperitoneal sarcoma management. <i>Journal of Surgical Oncology</i> , 2018, 117, 87-92.	1.7	13
168	Clinical and Molecular Spectrum of Liposarcoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 151-159.	1.6	183
169	Perspectives on the evolving state of the art management of gastrointestinal stromal tumours. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 21-21.	3.0	3
170	Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review. <i>Cancers</i> , 2018, 10, 417.	3.7	36
171	Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv79-iv95.	1.2	380
172	Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma. <i>Medical Oncology</i> , 2018, 35, 138.	2.5	26
173	Age-related sarcoma patient experience: results from a national survey in England. <i>BMC Cancer</i> , 2018, 18, 991.	2.6	28
174	Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response. <i>Clinical Sarcoma Research</i> , 2018, 8, 13.	2.3	32
175	Preserving quality of life as a key treatment goal in advanced soft tissue sarcomas. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1241-1248.	2.4	3
176	Trends in Modern Phase 1 Oncology Trials. <i>New England Journal of Medicine</i> , 2018, 379, 1188-1189.	27.0	3
177	Synovial Sarcoma of the Thyroid Gland, Diagnostic Pitfalls and Clinical Management. <i>Anticancer Research</i> , 2018, 38, 5275-5282.	1.1	6
178	Advances in the treatment of soft tissue sarcoma: focus on eribulin. <i>Cancer Management and Research</i> , 2018, Volume 10, 207-216.	1.9	9
179	Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv68-iv78.	1.2	413
180	Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv51-iv67.	1.2	641

#	ARTICLE	IF	CITATIONS
181	Quality of life and patientsâ€™ expectations in soft tissue sarcoma. <i>Future Oncology</i> , 2018, 14, 51-62.	2.4	12
182	Acral myxoinflammatory fibroblastic sarcoma with hybrid features of hemosiderotic fibrolipomatous tumor occurring 10â€“years after renal transplantation. <i>Rare Tumors</i> , 2018, 10, 203636131878262.	0.6	4
183	Pancreaticoduodenectomy for the Management of Pancreatic or Duodenal Metastases from Primary Sarcoma. <i>Anticancer Research</i> , 2018, 38, 4041-4046.	1.1	4
184	2018 ESMO Sarcoma and GIST Symposium: â€“take-home messagesâ€“ in soft tissue sarcoma. <i>ESMO Open</i> , 2018, 3, e000390.	4.5	6
185	Riskâ€“benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling. <i>Future Oncology</i> , 2018, 14, 2663-2676.	2.4	105
186	Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. <i>Annals of Oncology</i> , 2018, 29, 1995-2002.	1.2	30
187	Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma. <i>Medical Oncology</i> , 2018, 35, 131.	2.5	14
188	The Value of Neoadjuvant Chemotherapy in Localized High-Risk Soft-Tissue Sarcoma of the Extremities and Trunk. <i>JAMA Oncology</i> , 2018, 4, 1167.	7.1	10
189	Abstract 616: Interferon gamma induced transformation of the cold tumor microenvironment in patients with NY-ESO-1 expressing sarcomas. , 2018, , .		1
190	Effect of intratumoral (IT) injection of the toll-like receptor 4 (TLR4) agonist G100 on a clinical response and CD4 T-cell response locally and systemically.. <i>Journal of Clinical Oncology</i> , 2018, 36, 71-71.	1.6	4
191	Clear Cell Sarcoma-like Tumor of the Gastrointestinal Tract: Clinical Outcome and Pathologic Features of a Molecularly Characterized Tertiary Center Case Series. <i>Anticancer Research</i> , 2018, 38, 1479-1483.	1.1	16
192	Gemcitabine re-challenge in metastatic soft tissue sarcoma: A therapeutic option for selected patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11559-11559.	1.6	0
193	TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS11590-TPS11590.	1.6	1
194	Lack of cardiac toxicity in patients treated with aldoxrubicin with doxorubicin equivalent doses beyond 1000mg/m2.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11585-11585.	1.6	1
195	Paediatric, adolescent, wild type, syndromic gastrointestinal stromal tumours (PAWS-GIST): Report from United Kingdom PAWS-GIST clinic.. <i>Journal of Clinical Oncology</i> , 2018, 36, e23519-e23519.	1.6	0
196	Detection of endoglin-expressing CTCs in patients enrolled in an adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS).. <i>Journal of Clinical Oncology</i> , 2018, 36, e23570-e23570.	1.6	0
197	The spectrum of EWSR1-rearranged neoplasms at a tertiary sarcoma centre; assessing 772 tumour specimens and the value of current ancillary molecular diagnostic modalities. <i>British Journal of Cancer</i> , 2017, 116, 669-678.	6.4	48
198	Novel therapeutic approaches in chondrosarcoma. <i>Future Oncology</i> , 2017, 13, 637-648.	2.4	96

#	ARTICLE	IF	CITATIONS
199	Phase III Soft Tissue Sarcoma Trials: Success or Failure?. Current Treatment Options in Oncology, 2017, 18, 19.	3.0	19
200	Tâ€cell infiltration and clonality correlate with programmed cell death protein 1 and programmed deathâ€ligand 1 expression in patients with soft tissue sarcomas. Cancer, 2017, 123, 3291-3304.	4.1	202
201	Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment, 2017, 164, 395-400.	2.5	12
202	Eribulin in advanced liposarcoma and leiomyosarcoma. Expert Review of Anticancer Therapy, 2017, 17, 717-723.	2.4	13
203	Treatment of retroperitoneal sarcoma: current standards and new developments. Current Opinion in Oncology, 2017, 29, 260-267.	2.4	56
204	Pazopanib, a promising option for the treatment of aggressive fibromatosis. Anti-Cancer Drugs, 2017, 28, 421-426.	1.4	36
205	The Adequacy of Core Biopsy in the Assessment of Smooth Muscle Neoplasms of Soft Tissues. American Journal of Surgical Pathology, 2017, 41, 923-931.	3.7	35
206	Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group. Annals of Oncology, 2017, 28, 1230-1242.	1.2	168
207	Qâ€TWIST: What really matters to the cancer patient?. Cancer, 2017, 123, 2200-2202.	4.1	12
208	Advances in the Pathology and Molecular Biology of Sarcomas and the Impact on Treatment. Clinical Oncology, 2017, 29, 471-480.	1.4	6
209	Treatment of soft tissue sarcoma: a focus on earlier stages. Future Oncology, 2017, 13, 13-21.	2.4	26
210	Olaratumab for the treatment of soft-tissue sarcoma. Future Oncology, 2017, 13, 2151-2157.	2.4	2
211	Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma. Medical Oncology, 2017, 34, 167.	2.5	35
212	Isolated limb perfusion for locally advanced angiosarcoma in extremities: A multi-centre study. European Journal of Cancer, 2017, 85, 114-121.	2.8	12
213	First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient. Journal of Immunotherapy, 2017, 40, 302-306.	2.4	51
214	Desmoplastic small round cell tumor: evaluation of reverse transcription-polymerase chain reaction and fluorescence in situ hybridization as ancillary molecular diagnostic techniques. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 631-640.	2.8	28
215	Does histotype-tailored neoadjuvant therapy improve outcomes?. Nature Reviews Clinical Oncology, 2017, 14, 589-590.	27.6	1
216	Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncology, The, 2017, 18, 1089-1103.	10.7	214

#	ARTICLE	IF	CITATIONS
217	Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. <i>Gynecologic Oncology</i> , 2017, 146, 531-537.	1.4	51
218	An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma Patients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). <i>Annals of Oncology</i> , 2017, 28, 2399-2408.	1.2	274
219	Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. <i>Acta Oncologica</i> , 2017, 56, 88-92.	1.8	146
220	Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. <i>Future Oncology</i> , 2017, 13, 93-107.	2.4	99
221	Promising novel therapeutic approaches in the management of gastrointestinal stromal tumors. <i>Future Oncology</i> , 2017, 13, 185-194.	2.4	8
222	The Current Landscape of Early Drug Development for Patients With Sarcoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 807-810.	3.8	3
223	A molecular signature predictive of clinical outcome following pazopanib therapy in advanced soft tissue sarcoma. <i>Annals of Oncology</i> , 2017, 28, x149.	1.2	2
224	Systemic Therapy in Metastatic or Unresectable Well-Differentiated/Dedifferentiated Liposarcoma. <i>Frontiers in Oncology</i> , 2017, 7, 292.	2.8	31
225	SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors. <i>Sarcoma</i> , 2017, 2017, 1-8.	1.3	55
226	Radiation induced angiosarcoma of the breast: outcomes from a retrospective case series. <i>Clinical Sarcoma Research</i> , 2017, 7, 15.	2.3	38
227	Myoepithelial Carcinoma of the Paracecal Mesentery: Aggressive Behavior of a Rare Neoplasm at an Unusual Anatomic Site. <i>Rare Tumors</i> , 2017, 9, 38-41.	0.6	3
228	Olaratumab: a platelet-derived growth factor receptor- $\alpha$ -blocking antibody for the treatment of soft tissue sarcoma. <i>Clinical Pharmacology: Advances and Applications</i> , 2017, Volume 9, 159-164.	1.2	4
229	Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. <i>Journal of Clinical Oncology</i> , 2017, 35, 3433-3439.	1.6	126
230	Title is missing!. , 2017, , .		5
231	Neoadjuvant chemotherapy in localised soft-tissue sarcomas: where do we go from here?. <i>Lancet Oncology</i> , The, 2017, 18, 706-707.	10.7	6
232	Abstract 2947: Intratumoral injection of the toll-like receptor 4 agonist G100 induces a T-cell response in the soft tissue sarcoma microenvironment. , 2017, , .		6
233	Clinical activity of BLU-285 in advanced gastrointestinal stromal tumor (GIST).. <i>Journal of Clinical Oncology</i> , 2017, 35, 11011-11011.	1.6	16
234	Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950).. <i>Journal of Clinical Oncology</i> , 2017, 35, 11058-11058.	1.6	21

#	ARTICLE	IF	CITATIONS
235	Anthracycline, gemcitabine, and pazopanib in epithelioid sarcoma: Results of a retrospective multi-institutional case series.. Journal of Clinical Oncology, 2017, 35, 11065-11065.	1.6	2
236	A randomized, double-blind, placebo-controlled, phase III study of crenolanib in advanced or metastatic GIST patients bearing a D842V mutation in <i>PDGFRA</i> : The CrenoGIST study.. Journal of Clinical Oncology, 2017, 35, TPS11080-TPS11080.	1.6	11
237	Tappas: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (AAS).. Journal of Clinical Oncology, 2017, 35, TPS11081-TPS11081.	1.6	5
238	Olaratumab for the treatment of soft tissue sarcoma. Drugs of Today, 2017, 53, 247.	1.1	6
239	Correlation of T-cell infiltration and clonality with PD-L1 expression in soft tissue sarcomas.. Journal of Clinical Oncology, 2017, 35, 23-23.	1.6	0
240	Does <i>MGMT</i> (O6-methylguanineâ€DNA methyltransferase) have a role in metastatic Ewing sarcoma (ES) patients (pts) undergoing temozolomide (TMZ) and irinotecan (IRI)?. Journal of Clinical Oncology, 2017, 35, 11030-11030.	1.6	0
241	Safety and efficacy of trabectedin when administered in the inpatient vs. outpatient setting in a subset analysis of a phase III randomized clinical trial.. Journal of Clinical Oncology, 2017, 35, e22516-e22516.	1.6	0
242	The Imaging and Pathological Features of Metastatic Leiomyosarcoma in the Gallbladder. Rare Tumors, 2016, 8, 179-181.	0.6	2
243	Soft Tissue Myoepithelial Carcinoma Metastatic to the Cecum: Highlighting an Unusual Metastatic Pattern and the Need for Diagnostic Awareness. Rare Tumors, 2016, 8, 20-23.	0.6	4
244	Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin. Cancer Management and Research, 2016, Volume 8, 95-104.	1.9	12
245	A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas. Sarcoma, 2016, 2016, 1-9.	1.3	27
246	Targeting gastrointestinal stromal tumors: the role of regorafenib. OncoTargets and Therapy, 2016, 9, 3009.	2.0	5
247	Patient perspective of the diagnostic sarcoma pathway; results from a national sarcoma patient survey in England. Annals of Oncology, 2016, 27, vi488.	1.2	0
248	Dedifferentiated Liposarcoma. Advances in Anatomic Pathology, 2016, 23, 30-40.	4.3	97
249	Epithelioid Sarcoma. Advances in Anatomic Pathology, 2016, 23, 41-49.	4.3	95
250	Cardiac safety and toxicity minimization of regorafenib treatment. Colorectal Cancer, 2016, 5, 1-3.	0.8	1
251	Dear John Hunter. BMJ, The, 2016, 355, i6515.	6.0	2
252	Preliminary safety and activity in a first-in-human phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT and PDGFRÎ± activation loop mutants in advanced gastrointestinal stromal tumor (GIST). European Journal of Cancer, 2016, 69, S4.	2.8	0



#	ARTICLE	IF	CITATIONS
253	Drug repositioning in sarcomas and other rare tumors. <i>EBioMedicine</i> , 2016, 6, 4-5.	6.1	4
254	Endosialin expression in soft tissue sarcoma as a potential marker of undifferentiated mesenchymal cells. <i>British Journal of Cancer</i> , 2016, 115, 473-479.	6.4	23
255	Dermatofibrosarcoma protuberans: pathology, genetics, and potential therapeutic strategies. <i>Annals of Diagnostic Pathology</i> , 2016, 25, 64-71.	1.3	124
256	Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. <i>Clinical Sarcoma Research</i> , 2016, 6, 15.	2.3	80
257	Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group. <i>Annals of Surgical Oncology</i> , 2016, 23, 3531-3540.	1.5	136
258	Desmoplastic Small Round Cell Tumor. <i>International Journal of Surgical Pathology</i> , 2016, 24, 672-684.	0.8	50
259	PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3898-3905.	1.6	151
260	Rare Aggressive Behavior of <i>MDM2</i> -Amplified Retroperitoneal Dedifferentiated Liposarcoma, with Brain, Lung and Subcutaneous Metastases. <i>Rare Tumors</i> , 2016, 8, 105-108.	0.6	5
261	Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis. <i>Annals of Oncology</i> , 2016, 27, vi488.	1.2	0
262	Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. <i>Lancet, The</i> , 2016, 388, 488-497.	13.7	512
263	Treatment of resectable intrathoracic sarcomas: a single institution experience over twenty years. <i>Journal of Radiation Oncology</i> , 2016, 5, 169-177.	0.7	3
264	The Current Status of Solitary Fibrous Tumor. <i>International Journal of Surgical Pathology</i> , 2016, 24, 281-292.	0.8	150
265	p.(L576P)-KIT mutation in GIST: Favorable prognosis and sensitive to imatinib?. <i>Cancer Biology and Therapy</i> , 2016, 17, 543-545.	3.4	6
266	Phosphoproteomics in translational research: a sarcoma perspective. <i>Annals of Oncology</i> , 2016, 27, 787-794.	1.2	34
267	Treatment of advanced soft tissue sarcoma: efficacy and safety of trabectedin, a multitarget agent, and update on other systemic therapeutic options. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 501-512.	3.1	4
268	Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancerâ€“Soft Tissue and Bone Sarcoma Group (EORTCâ€“STBSG) recommendations for pathological examination and reporting. <i>European Journal of Cancer</i> , 2016, 53, 84-95.	2.8	99
269	The state of Illinois obstetric hemorrhage project: pre-project and post-training examination scores. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2016, 29, 845-849.	1.5	9
270	Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 786-793.	1.6	647

#	ARTICLE	IF	CITATIONS
271	Histology-Driven Therapy. International Journal of Surgical Pathology, 2016, 24, 5-15.	0.8	34
272	Patient-reported outcomes from randomized, phase-3 study of trabectedin (T) vs. dacarbazine (D) in advanced leiomyosarcoma (LMS) or liposarcoma (LPS).. Journal of Clinical Oncology, 2016, 34, 11061-11061.	1.6	5
273	Single-agent LV305 to induce anti-tumor immune and clinical responses in patients with advanced or metastatic sarcoma and other cancers expressing NY-ESO-1.. Journal of Clinical Oncology, 2016, 34, 3093-3093.	1.6	3
274	Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas. Indian Journal of Medical and Paediatric Oncology, 2016, 37, 125-130.	0.2	3
275	Using G100 (Glucopyranosyl Lipid A) to transform the sarcoma tumor immune microenvironment.. Journal of Clinical Oncology, 2016, 34, 11017-11017.	1.6	0
276	Temozolamide and irinotecan in metastatic Ewing sarcoma: An Italian Sarcoma Group and Royal Marsden Hospital join study.. Journal of Clinical Oncology, 2016, 34, 11033-11033.	1.6	0
277	3444 Low dose oral cyclophosphamide (LDOC) with prednisolone in the treatment of advanced adult soft tissue sarcoma (STS). European Journal of Cancer, 2015, 51, S703.	2.8	0
278	Clinical trial design methodologies for advanced sarcoma therapy. Clinical Research and Regulatory Affairs, 2015, 32, 70-73.	2.1	0
279	1321 Efficacy and safety of trabectedin (T) or dacarbazine (D) in an elderly patient subgroup (65 years) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) after prior chemotherapy. European Journal of Cancer, 2015, 51, S194.	2.8	0
280	2026 A Phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer. European Journal of Cancer, 2015, 51, S336-S337.	2.8	0
281	The effect of surgery with radiation on pelvic Ewing sarcoma survival. Journal of Surgical Oncology, 2015, 112, 861-865.	1.7	17
282	Synovial sarcoma diagnosis and management in the era of targeted therapies. Current Opinion in Oncology, 2015, 27, 316-322.	2.4	25
283	Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma. Rare Tumors, 2015, 7, 86-88.	0.6	30
284	Trabectedin in Soft Tissue Sarcomas. Marine Drugs, 2015, 13, 974-983.	4.6	16
285	Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy. Frontiers in Oncology, 2015, 5, 186.	2.8	34
286	Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy. Annals of Oncology, 2015, 26, 75-80.	1.2	95
287	Cardio-oncology: a special focus issue fromFuture Oncology. Future Oncology, 2015, 11, 1993-1994.	2.4	0
288	Cardio-oncology: an ongoing evolution. Future Oncology, 2015, 11, 2059-2066.	2.4	12

#	ARTICLE	IF	CITATIONS
289	Redefining the standard of care in metastatic leiomyosarcoma. Lancet Oncology, The, 2015, 16, 360-362.	10.7	5
290	Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors. Clinical Cancer Research, 2015, 21, 693-700.	7.0	81
291	A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma. Clinical Sarcoma Research, 2015, 5, 13.	2.3	44
292	Treatment of Chest Wall Sarcomas. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 80-86.	1.3	16
293	Quality of life measures in soft tissue sarcoma. Expert Review of Anticancer Therapy, 2015, 15, 95-100.	2.4	18
294	Current and advancing systemic treatment options for soft tissue sarcomas. Expert Opinion on Pharmacotherapy, 2015, 16, 2023-2037.	1.8	1
295	A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 2015, 76, 777-784.	2.3	17
296	A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor $\alpha$ (PDGFR $\alpha$ ) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS).. Journal of Clinical Oncology, 2015, 33, 10501-10501.	1.6	15
297	A phase I/II clinical trial of belinostat (PXD101) in combination with doxorubicin in patients with soft tissue sarcomas (STS).. Journal of Clinical Oncology, 2015, 33, 10516-10516.	1.6	3
298	Phase I, first-in-human trial of LV305 in patients with advanced or metastatic cancer expressing NY-ESO-1.. Journal of Clinical Oncology, 2015, 33, 3021-3021.	1.6	8
299	Dermatofibrosarcoma protuberans: from translocation to targeted therapy. Cancer Biology and Medicine, 2015, 12, 375-84.	3.0	39
300	PM00104 (Zalypsis <sup>®</sup> ): A Marine Derived Alkylating Agent. Molecules, 2014, 19, 12328-12335.	3.8	28
301	Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8+ T cells. , 2014, 2, 36.		57
302	Success Is Not Final and Failure Is Not Fatal. Journal of Clinical Oncology, 2014, 32, 3449-3450.	1.6	0
303	Analysis of Clinical Prognostic Factors for Adult Patients with Head and Neck Sarcomas. Otolaryngology - Head and Neck Surgery, 2014, 151, 976-983.	1.9	22
304	The multidisciplinary management of giant cell tumor of bone. Expert Review of Anticancer Therapy, 2014, 14, 783-790.	2.4	13
305	Inference of Tumor Evolution during Chemotherapy by Computational Modeling and In Situ Analysis of Genetic and Phenotypic Cellular Diversity. Cell Reports, 2014, 6, 514-527.	6.4	239
306	Systemic therapy in advanced uterine adenosarcoma with sarcomatous overgrowth. Gynecologic Oncology, 2014, 132, 513.	1.4	4

#	ARTICLE	IF	CITATIONS
307	A Phase II multicenter, open-label, clinical and pharmacokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors. <i>Investigational New Drugs</i> , 2014, 32, 171-177.	2.6	11
308	Myxoid Liposarcomas Demonstrate a Profound Response to Neoadjuvant Radiation Therapy: An MRI-Based Volumetric Analysis and Pathological Correlation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, S756-S757.	0.8	4
309	A Contemporary Large Single-Institution Evaluation of Resected Retroperitoneal Sarcoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 2150-2158.	1.5	65
310	Management and outcome of metastatic clear cell sarcoma. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1383.	1.0	2
311	Molecular profiling of soft tissue sarcomas using next-generation sequencing: a pilot study toward precision therapeutics. <i>Human Pathology</i> , 2014, 45, 1563-1571.	2.0	42
312	Trivalent ganglioside vaccine and immunologic adjuvant versus adjuvant alone in metastatic sarcoma patients rendered disease-free by surgery: A randomized phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10520-10520.	1.6	14
313	Gemcitabine (G) and docetaxel (D) in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10541-10541.	1.6	1
314	Delayed development of a rhabdomyosarcoma following radiation for a spinal cord glioma. <i>Journal of Neuro-Oncology</i> , 2013, 112, 115-118.	2.9	5
315	Clinical benefit of trabectedin in uterine adenosarcoma. <i>Medical Oncology</i> , 2013, 30, 501.	2.5	20
316	The Use of Radiofrequency Ablation in Gastrointestinal Stromal Tumor. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 751.	0.5	0
317	The evolution of systemic therapy in sarcoma. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 211-223.	2.4	23
318	Treatment of Resectable Intrathoracic Sarcomas: A Single Institution Experience Over 20 Years. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, S617.	0.8	0
319	An evaluation of [ <sup>18</sup> F]â€“fluorodeoxyâ€“D-glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing Sarcoma. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1113-1117.	1.5	74
320	KIT signaling regulates primordial follicle formation in the neonatal mouse ovary. <i>Developmental Biology</i> , 2013, 382, 186-197.	2.0	60
321	Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2013, 381, 295-302.	13.7	1,144
322	Management of gastrointestinal stromal tumors. <i>Future Oncology</i> , 2013, 9, 193-206.	2.4	28
323	The efficacy of caffeine-potentiated chemotherapy in clear cell sarcoma. <i>International Journal of Clinical Oncology</i> , 2013, 18, 356-356.	2.2	0
324	New drugs and clinical trial design in advanced sarcoma: have we made any progress?. <i>Future Oncology</i> , 2013, 9, 1409-1411.	2.4	7

#	ARTICLE	IF	CITATIONS
325	Diagnosis, prognosis, and management of leiomyosarcoma. Current Opinion in Oncology, 2013, 25, 384-389.	2.4	41
326	Phase I Trial of Preoperative Chemoradiation plus Sorafenib for High-Risk Extremity Soft Tissue Sarcomas with Dynamic Contrast-Enhanced MRI Correlates. Clinical Cancer Research, 2013, 19, 6902-6911.	7.0	61
327	Multiple Liver Abscess Formation and Primary Gastrointestinal Stromal Tumor. Rare Tumors, 2013, 5, 167-168.	0.6	2
328	Clinical Activity and Tolerability of a 14-Day Infusional Ifosfamide Schedule in Soft-Tissue Sarcoma. Sarcoma, 2013, 2013, 1-6.	1.3	54
329	Role of the Antiapoptotic Proteins BCL2 and MCL1 in the Neonatal Mouse Ovary1. Biology of Reproduction, 2013, 88, 46.	2.7	25
330	Bone Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 688-723.	4.9	106
331	Impact of 18F-FDG PET/CT Imaging in Therapeutic Decisions for Malignant Solitary Fibrous Tumor of the Pelvis. Clinical Nuclear Medicine, 2013, 38, 453-455.	1.3	11
332	Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib. OncoTargets and Therapy, 2013, 6, 217.	2.0	16
333	Abstract C47: Inference of tumor evolution during chemotherapy by computational modeling and single cell analysis of diversity.. , 2013, , .		0
334	Abstract P1-08-03: Prediction of response to neoadjuvant chemotherapy in estrogen receptor positive (ER+) breast cancer by IHC4 or Ki67 alone. , 2013, , .		0
335	Systemic therapy in primary angiosarcoma of the spleen. Rare Tumors, 2012, 4, 178-180.	0.6	19
336	Role of Palliative Chemotherapy in Advanced Epithelioid Sarcoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 351-357.	1.3	54
337	Reducing Maternal Deaths Through State Maternal Mortality Review. Journal of Women's Health, 2012, 21, 905-909.	3.3	33
338	Treatment of Chest Wall Sarcomas: A Single Institution Experience Over 20 Years. International Journal of Radiation Oncology Biology Physics, 2012, 84, S658.	0.8	1
339	Conventional anthracycline-based chemotherapy has limited efficacy in solitary fibrous tumour. Acta Oncol <sup>3</sup> gica, 2012, 51, 550-554.	1.8	44
340	Molecular Classification of Breast Cancer. Surgical Pathology Clinics, 2012, 5, 701-717.	1.7	10
341	MDM2 inhibition in liposarcoma: a step in the right direction. Lancet Oncology, The, 2012, 13, 1070-1071.	10.7	15
342	NYA <sup>ES</sup> is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer, 2012, 118, 4564-4570.	4.1	107

#	ARTICLE	IF	CITATIONS
343	Know Before They Go: A Time/Cost Analysis of an Early Screening and Referral Pilot Program for Postpartum Depression. JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing, 2012, 41, S23-S24.	0.5	0
344	NYESO-1/LAGE-1s and PRAME Are Targets for Antigen Specific T Cells in Chondrosarcoma following Treatment with 5-Aza-2-Deoxycytidine. PLoS ONE, 2012, 7, e32165.	2.5	52
345	Advanced aggressive fibromatosis: Effective palliation with chemotherapy. Acta Oncologica, 2011, 50, 455-461.	1.8	55
346	Leiomyosarcomas of the inferior vena cava: diagnostic features on cross-sectional imaging. Clinical Radiology, 2011, 66, 50-56.	1.1	48
347	Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. European Journal of Cancer, 2011, 47, 138-150.	2.8	124
348	Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study. European Journal of Cancer, 2011, 47, 1006-1012.	2.8	88
349	Immune-Based Therapies for Sarcoma. Sarcoma, 2011, 2011, 1-7.	1.3	29
350	Trabectedin in advanced uterine leiomyosarcomas: A retrospective case series analysis from two reference centers. Gynecologic Oncology, 2011, 123, 553-556.	1.4	68
351	Clinical benefit of early phase clinical trial participation for advanced sarcoma patients. Cancer Chemotherapy and Pharmacology, 2011, 68, 423-429.	2.3	14
352	Chemotherapy in clear cell sarcoma. Medical Oncology, 2011, 28, 859-863.	2.5	58
353	Nuclear NF- $\kappa$ B/p53 expression and response to neoadjuvant chemotherapy in breast cancer. Journal of Clinical Pathology, 2011, 64, 130-135.	2.0	25
354	Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations. Sarcoma, 2011, 2011, 1-13.	1.3	54
355	Fungal spinal cord compression in metastatic synovial sarcoma. Acta Oncologica, 2011, 50, 158-159.	1.8	3
356	Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial.. Journal of Clinical Oncology, 2011, 29, 10000-10000.	1.6	13
357	Creatinine clearance and serum albumin as factors for encephalopathy with ambulatory 14-day infusional ifosfamide for advanced liposarcomas.. Journal of Clinical Oncology, 2011, 29, 10087-10087.	1.6	0
358	Biological Rationale and Current Clinical Experience With Anti-Insulin-Like Growth Factor 1 Receptor Monoclonal Antibodies in Treating Sarcoma. Cancer Journal (Sudbury, Mass ), 2010, 16, 183-194.	2.0	63
359	Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Research and Treatment, 2010, 119, 315-323.	2.5	98
360	Beyond triple-negative breast cancer: the need to define new subtypes. Expert Review of Anticancer Therapy, 2010, 10, 1197-1213.	2.4	18

#	ARTICLE	IF	CITATIONS
361	Clinical Benefit of Second-Line Palliative Chemotherapy in Advanced Soft-Tissue Sarcoma. <i>Sarcoma</i> , 2010, 2010, 1-8.	1.3	24
362	PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study. <i>Modern Pathology</i> , 2010, 23, 1334-1345.	5.5	61
363	Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma. <i>European Journal of Surgical Oncology</i> , 2010, 36, 477-482.	1.0	83
364	Atypical metastatic profile in Stewart-Treves syndrome. <i>Acta OncolÃ³gica</i> , 2010, 49, 1388-1390.	1.8	0
365	Systemic therapy in clear cell sarcoma.. <i>Journal of Clinical Oncology</i> , 2010, 28, 10098-10098.	1.6	1
366	Nuclear NF-kb/p65 expression and response to neoadjuvant chemotherapy in breast cancer.. <i>Journal of Clinical Oncology</i> , 2010, 28, 611-611.	1.6	2
367	A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer. <i>British Journal of Cancer</i> , 2009, 100, 305-310.	6.4	36
368	A feasibility study of sequential doublet chemotherapy comprising carboplatinâ€doxorubicin and carboplatinâ€paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma. <i>Annals of Oncology</i> , 2009, 20, 1787-1793.	1.2	10
369	Genomic profile of a secretory breast cancer with an ETV6-NTRK3 duplication. <i>Journal of Clinical Pathology</i> , 2009, 62, 604-612.	2.0	46
370	The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 53-68.	2.5	244
371	Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. <i>European Journal of Cancer</i> , 2009, 45, 2930-2934.	2.8	113
372	Biomarkers and predictive factors of response to neoadjuvant treatment. <i>Breast Cancer Research</i> , 2009, 11, .	5.0	0
373	9421 The role of chemotherapy in aggressive fibromatosis. <i>European Journal of Cancer, Supplement</i> , 2009, 7, 596.	2.2	0
374	Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 245-256.	2.5	62
375	Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. <i>Breast Cancer Research and Treatment</i> , 2008, 111, 27-44.	2.5	287
376	Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 1311-1317.	1.5	50
377	Outcome of high-dose cytarabine-based induction therapy followed by hematopoietic stem cell transplantation in acute myeloid leukemia: influence of karyotype. <i>Leukemia and Lymphoma</i> , 2008, 49, 2284-2290.	1.3	2
378	Paclitaxel in the management of ovarian cancer. <i>Expert Review of Obstetrics and Gynecology</i> , 2008, 3, 287-299.	0.4	0



#	ARTICLE	IF	CITATIONS
379	Methylated <i>NEUROD1</i> Promoter is a Marker for Chemosensitivity in Breast Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 3494-3502.	7.0	37
380	Debulking Hepatectomy for an Unusual Case of a Grade 1 Stage 1 Granulosa Cell Tumour of the Ovary with Late Metastases. <i>Oncology</i> , 2007, 72, 143-144.	1.9	5
381	Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. <i>Lancet Oncology</i> , The, 2007, 8, 595-602.	10.7	416
382	Caveolin 1 Is Overexpressed and Amplified in a Subset of Basal-like and Metaplastic Breast Carcinomas: A Morphologic, Ultrastructural, Immunohistochemical, and <i>In situ</i> Hybridization Analysis. <i>Clinical Cancer Research</i> , 2007, 13, 90-101.	7.0	202
383	Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2007, 106, 181-189.	2.5	101
384	Anthracycline cardiotoxicity. <i>Expert Opinion on Drug Safety</i> , 2006, 5, 791-809.	2.4	108
385	Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1249-1269.	2.4	75
386	Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response. <i>Lancet Oncology</i> , The, 2006, 7, 869-874.	10.7	60
387	Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue. <i>Modern Pathology</i> , 2006, 19, 307-319.	5.5	87
388	Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic <i>in situ</i> hybridisation analysis. <i>Modern Pathology</i> , 2006, 19, 999-1009.	5.5	143
389	MYC amplification in breast cancer: a chromogenic <i>in situ</i> hybridisation study. <i>Journal of Clinical Pathology</i> , 2006, 60, 1017-1023.	2.0	58
390	Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma. <i>British Journal of Cancer</i> , 2006, 94, 358-362.	6.4	96
391	The development and application of imatinib. <i>Expert Opinion on Drug Safety</i> , 2005, 4, 183-191.	2.4	37
392	Use of endomyocardial biopsy to assess anthracycline-induced cardiotoxicity. <i>Lancet Oncology</i> , The, 2005, 6, 67.	10.7	7
393	Differential sensitivity of liposarcoma subtypes to chemotherapy. <i>European Journal of Cancer</i> , 2005, 41, 2853-2860.	2.8	290
394	Tumour vaccine associated lymphadenopathy and false positive positron emission tomography scan changes. <i>British Journal of Radiology</i> , 2004, 77, 74-75.	2.2	35
395	Efficacy and safety of trastuzumab. <i>Expert Opinion on Drug Safety</i> , 2004, 3, 317-327.	2.4	23
396	Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin. <i>Lancet Oncology</i> , The, 2004, 5, 575-577.	10.7	21

#	ARTICLE	IF	CITATIONS
397	Clinical and Molecular Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated with 5-Fluorouracil-Based Chemotherapy. Clinical Colorectal Cancer, 2003, 2, 235-238.	2.3	0
398	Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?. British Journal of Cancer, 2003, 89, 36-42.	6.4	68
399	Virtual Biopsy in Soft Tissue Sarcoma. How Close Are We?. Frontiers in Oncology, 0, 12, .	2.8	6